“We have to price our medicines in a way that’s reflective of the value they create. And we have to be comfortable with the fact that if our medicines aren’t creating enough value for society, then people aren’t going to want to pay for them.”
Vasant Narasimhan, M.D., is the CEO of Novartis. He has led a strategic and cultural transformation to build a leading medicines company globally powered by advanced therapy platforms and data science. Under his leadership, the company has completed over $70 billion in strategic transactions and licensed over 30 novel medicines including cell and gene therapies and vaccines.
Prior to his role as CEO, Dr. Narasimhan was the Global Head of Drug Development and Chief Medical Officer. He also held a range of leadership roles in product development and general management as the Global Head of Development for Novartis Pharmaceuticals, Global Head of the Sandoz Biopharmaceuticals and Oncology Injectables business unit, Global Head of Development for Novartis Vaccines, North America Region Head for Novartis Vaccines, and United States Country President for Novartis Vaccines and Diagnostics.
Dr. Narasimhan earned his B.A. in biological sciences from the University of Chicago, his M.D. from Harvard Medical School, and his M.P.P. from Harvard Kennedy School of Government. During and after his medical studies, he worked on a range of public health issues in low- and middle-income countries, and continues to champion global health priorities today. He currently sits on the Boards of Harvard Medical School; African Parks, a nonprofit conservation organization; and the Pharmaceutical Research and Manufacturers of America (PhRMA). Named one of FORTUNE’s 40 Under 40, Dr. Narasimhan is a member of the National Academy of Medicine and the World 50.